Syngenis banks $4M pre-float to power AI-driven biotech platform
Australia has no shortage of world-class medical researchers. What it has traditionally lacked is a seamless pathway to transform clever science into commercial medicines without sending promising discoveries offshore. That is the gap Syngenis Labs is now aiming to close.
The Perth-based biotech has completed an oversubscribed $4 million pre-float capital raising that will fast-track development of a business designed to capture far more value from Australia’s rapidly expanding genetic medicine sector.
Rather than focusing on a single therapeutic candidate, Syngenis says it’s building an entire ecosystem capable of taking RNA and DNA-based medicines from computer-generated concepts through to clinical-grade manufacturing under one roof.
The raise attracted sophisticated investors through Euroz Hartleys and appears well timed as global demand for RNA therapeutics, diagnostics and specialist manufacturing capacity continues to ramp up following years of advances in genetic medicine.
The global success of mRNA vaccines during the COVID-19 pandemic transformed RNA-based medicine from a promising technology into one of the fastest-growing fields in healthcare, sparking billions of dollars of investment worldwide. Since then, RNA and oligonucleotide therapies have emerged as highly targeted treatments for cancer, neurological disorders, cardiometabolic diseases, rare conditions and inherited genetic illnesses.
Oligonucleotide therapeutics are short, laboratory-made genetic sequences that work directly at a cellular level, enabling scientists to switch off harmful genes or precisely target disease-causing biological pathways.
Positioned to capitalise on that rapidly expanding market, Perth-based Syngenis has built specialist expertise in DNA and RNA assay design and oligonucleotide synthesis. The company now supports researchers and biotechnology groups in Australia and overseas, developing next-generation diagnostic tools and precision medicines that are increasingly shaping the future of healthcare and rapid pathogen detection.
And while many biotechnology companies specialise in one small part of the development chain, Syngenis believes controlling the entire process will provide it with a significant competitive advantage.
Completing this $4 million pre-IPO raise is an important validation of the Syngenis strategy and the quality of the platform we are building. We are building out all six of our connected divisions in parallel, so that by the time we reach a listing the market is looking at a diversified, integrated platform rather than a single bet.
At the heart of the strategy is the company’s proprietary artificial intelligence platform, known as Discovery AI. Instead of simply analysing biological data, the system identifies potential therapeutic targets, designs RNA and DNA candidates, screens them computationally and prepares them for laboratory validation through a single integrated workflow.
That capability feeds directly into Syngenis’ existing research-grade manufacturing business, which has been operating for more than six years and already generates commercial revenue from universities, biotechnology companies, diagnostic developers and contract research organisations.
Perhaps the most significant investment from the latest raising will be construction of the company’s Good Manufacturing Practice (GMP) facility, targeted to become operational in January next year.
Once complete, the facility is expected to position Syngenis among a very small number of laboratories capable of manufacturing human-grade oligonucleotide products suitable for clinical trials, while also expanding into specialised chemistries such as phosphorodiamidate morpholino oligomers, which are produced by only a handful of manufacturers globally.
Notably, the company is simultaneously developing a second artificial intelligence engine designed to simulate clinical trials before patients are enrolled, potentially helping developers identify risks, refine study designs and reduce development costs well before expensive human testing begins.
Management says the Discovery AI platform has already designed its first therapeutic candidate, providing an early demonstration that the technology is progressing beyond theory into practical drug development.
The fresh capital will also support expansion across five additional business divisions, collectively broadening the company’s commercial reach.
These include specialist clinical research services for nucleic acid medicines, an affordable whole-genome testing business and two planned investment funds that will back promising RNA and DNA projects. The structure allows Syngenis to share in the upside of successful programs without carrying all of the development costs and risks itself.
That diversified approach could prove one of the company’s biggest strengths. Instead of pinning its future on a single drug candidate – a strategy that has undone many biotechnology companies – Syngenis is building multiple revenue streams around the same underlying technology platform.
The company also appears well placed to benefit from a structural shift that extends well beyond biotechnology. In the wake of the pandemic, governments around the world have boosted investment in sovereign biotechnology capability, recognising the strategic importance of local manufacturing, biosecurity and advanced medical research.
The company says the oversubscribed raising has strengthened its balance sheet ahead of a proposed ASX listing and provides the capital needed to mature each division into a scalable commercial business.
If management executes as planned, the market may ultimately view Syngenis less as a junior biotech with early revenue and more as critical infrastructure underpinning Australia’s next generation of genetic medicine. In a sector where integrated capability remains rare, that could prove a valuable position to occupy.
Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au
